Al-Khatib, S. M., Mulder, H., Wojdyla, D., Lopes, R. D., Wallentin, L., Alexander, J. H., … Granger, C. B. (2021). Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circulation. Arrhythmia and Electrophysiology, 14(3), e009614. https://doi.org/10.1161/circep.120.009614

Al-Khatib, Sana M., Hillary Mulder, Daniel Wojdyla, Renato D. Lopes, Lars Wallentin, John H. Alexander, Ziad Hijazi, Shinya Goto, and Christopher B. Granger. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.” Circulation. Arrhythmia and Electrophysiology 14, no. 3 (March 2021): e009614. https://doi.org/10.1161/circep.120.009614.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circulation Arrhythmia and electrophysiology. 2021 Mar;14(3):e009614.

Al-Khatib, Sana M., et al. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.” Circulation. Arrhythmia and Electrophysiology, vol. 14, no. 3, Mar. 2021, p. e009614. Epmc, doi:10.1161/circep.120.009614.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, Hijazi Z, Goto S, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circulation Arrhythmia and electrophysiology. 2021 Mar;14(3):e009614.